^
    Apply
    CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (NCT04375631)
    Phase 1
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/03/2020
    Primary completion :
    02/28/2027
    Completion :
    03/17/2027
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    cytarabine • cyclophosphamide • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • cyclosporin A microemulsion • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS (NCT04708054)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    10/21/2021
    Primary completion :
    12/31/2027
    Completion :
    12/31/2027
    KRAS • NRAS • DNMT3A • NF1 • RUNX1 • ASXL1 • PTPN1
    |
    TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation
    |
    Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan
    IO-202 as Monotherapy and IO-202 Plus Azacitidine ± Venetoclax in Patients in AML and CMML (IO-202-CL-001) (NCT04372433)
    Phase 1
    Immune-Onc Therapeutics
    Completed
    Last update posted :
    02/14/2025
    Initiation :
    09/14/2020
    Primary completion :
    01/31/2025
    Completion :
    01/31/2025
    LILRB4
    |
    Venclexta (venetoclax) • azacitidine • IO-202
    The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study (APAL2020SC) (NCT04726241)
    Phase 1/2
    LLS PedAL Initiative, LLC
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    04/18/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    KMT2A
    |
    KMT2A rearrangement • MLL rearrangement
    Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome (P30CA016672) (NCT03383575)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    01/17/2018
    Primary completion :
    02/28/2027
    Completion :
    02/28/2027
    TP53 • IDH2 • RUNX1 • ASXL1
    |
    IDH2 mutation • RUNX1 mutation • ASXL1 mutation • EZH2 mutation
    |
    azacitidine • Idhifa (enasidenib)
    Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (NCI-2018-01812) (NCT03672539)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    11/07/2018
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    CD33
    |
    CD33 positive
    |
    Mylotarg (gemtuzumab ozogamicin) • Vyxeos (cytarabine/daunorubicin liposomal formulation)
    Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. (NCT06071624)
    Phase 1
    Huda Salman
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    02/21/2024
    Primary completion :
    12/01/2028
    Completion :
    12/01/2043
    CD4
    |
    ICG122
    211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia (NCT03128034)
    Phase 1/2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    10/24/2017
    Primary completion :
    06/30/2027
    Completion :
    03/31/2029
    HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C
    |
    sirolimus • fludarabine IV • cyclosporin A microemulsion
    Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm (NCT05600894)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    06/27/2023
    Primary completion :
    08/31/2025
    Completion :
    08/31/2025
    BRAF
    |
    Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine)
    Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes (NCT04802161)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/07/2025
    Initiation :
    08/24/2022
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    RUNX1 • SF3B1 • ASXL1 • SRSF2 • BCOR • U2AF1 • STAG2 • ZRSR2
    |
    Chr del(11q)
    |
    Vyxeos (cytarabine/daunorubicin liposomal formulation) • pomalidomide • thalidomide
    Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia (NCI-2009-01173) (NCT00843882)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    01/29/2009
    Primary completion :
    07/08/2019
    Completion :
    10/02/2025
    PTPRC • CDC25C • GNRP
    |
    lenalidomide • Retacrit (epoetin alfa-epbx)
    211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome (NCI-2018-01788) (NCT03670966)
    Phase 1/2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    07/10/2019
    Primary completion :
    06/28/2027
    Completion :
    03/20/2029
    HLA-DRB1 • HLA-B
    |
    cyclophosphamide • sirolimus • fludarabine IV • Iomab-B (I-131-apamistamab) • cyclophosphamide intravenous
    Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (MT2015-29) (NCT03314974)
    Phase 2
    Masonic Cancer Center, University of Minnesota
    Recruiting
    Last update posted :
    02/04/2025
    Initiation :
    03/30/2018
    Primary completion :
    06/10/2025
    Completion :
    06/10/2026
    NPM1 • KMT2A • IKZF1 • CEBPA
    |
    NPM1 mutation • MLL rearrangement
    |
    cyclophosphamide
    Study of Tagraxofusp for Post-Transplant Maintenance for Patients with CD 123+ AML, MF and CMML (HSCT 002) (NCT05233618)
    Phase 1
    Karen Ballen, MD
    Recruiting
    Last update posted :
    02/03/2025
    Initiation :
    07/13/2022
    Primary completion :
    07/01/2026
    Completion :
    10/01/2026
    IL3RA
    |
    Elzonris (tagraxofusp-erzs) • SL-701
    Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation (NCI-2022-02837) (NCT05282459)
    Phase 1/2
    Stanford University
    Active, not recruiting
    Last update posted :
    09/26/2024
    Initiation :
    01/12/2022
    Primary completion :
    01/01/2025
    Completion :
    04/01/2025
    IDH2
    |
    IDH2 mutation
    |
    Idhifa (enasidenib)
    IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT (NCT04522895)
    Phase 2
    Heinrich-Heine University, Duesseldorf
    Completed
    Last update posted :
    09/19/2024
    Initiation :
    08/27/2020
    Primary completion :
    07/24/2024
    Completion :
    07/24/2024
    IDH2
    |
    IDH2 mutation
    |
    Idhifa (enasidenib)
    A Study of E7820 in People With Bone Marrow (Myeloid) Cancers (NCT05024994)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    07/03/2024
    Initiation :
    08/13/2021
    Primary completion :
    08/01/2025
    Completion :
    08/01/2025
    FLT3 • IDH1 • SF3B1 • SRSF2 • U2AF1 • ZRSR2
    |
    IDH2 mutation • FLT3 mutation • SF3B1 mutation • SRSF2 mutation • U2AF1 mutation • ZRSR2 mutation
    |
    E7820
    A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT (NCT03912064)
    Phase 1
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    06/11/2024
    Initiation :
    07/10/2019
    Primary completion :
    05/24/2024
    Completion :
    07/01/2024
    IL2RA • ISG20
    |
    Yervoy (ipilimumab) • CD25hi Treg depleted DLI
    HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (OPTIMIZE) (NCT06001385)
    Phase 2
    Center for International Blood and Marrow Trans...
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    12/08/2023
    Primary completion :
    02/01/2026
    Completion :
    06/30/2026
    HLA-DRB1 • HLA-B • HLA-DPB1 • HLA-C
    |
    cyclophosphamide • melphalan • fludarabine IV • mesna • busulfan
    Personalized NK Cell Therapy in CBT (NCT02727803)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    05/19/2016
    Primary completion :
    05/31/2025
    Completion :
    05/31/2025
    FLT3 • BCL2
    |
    FLT3 mutation
    |
    Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • Truxima (rituximab-abbs) • fludarabine IV • Riabni (rituximab-arrx) • busulfan • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • Novex (rituximab biosimilar) • cyclophosphamide intravenous
    Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations (NCT04603001)
    Phase 1
    Eli Lilly and Company
    Active, not recruiting
    Last update posted :
    06/05/2024
    Initiation :
    12/01/2020
    Primary completion :
    07/03/2023
    Completion :
    05/01/2025
    IDH1 • IDH2
    |
    IDH2 mutation • IDH1 R132 • IDH2 R140 • IDH2 R172
    |
    Venclexta (venetoclax) • azacitidine • LY3410738
    Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy (CYTOK-AZA) (NCT06439199)
    Phase N/A
    Nantes University Hospital
    Not yet recruiting
    Last update posted :
    06/03/2024
    Initiation :
    06/15/2024
    Primary completion :
    04/15/2026
    Completion :
    12/15/2026
    IL6 • TNFA • CXCL8 • IL10 • CSF2 • IL18 • IL17A • IL15 • IL1B
    |
    azacitidine
    Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations (NCI-2020-05261) (NCT04493138)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    07/21/2020
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    TP53 • FLT3 • ASXL1
    |
    TP53 mutation • FLT3-ITD mutation • ASXL1 mutation • CBL mutation
    |
    azacitidine • Vanflyta (quizartinib)
    Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant (NCI-2017-01069) (NCT03192397)
    Phase 1/2
    Roswell Park Cancer Institute
    Active, not recruiting
    Last update posted :
    05/29/2024
    Initiation :
    08/09/2017
    Primary completion :
    08/21/2023
    Completion :
    05/21/2027
    HLA-DRB1
    |
    cyclophosphamide • sirolimus • melphalan • fludarabine IV • captisol-enabled melphalan • cyclophosphamide intravenous
    A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) (NCT04609826)
    Phase 1
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    11/26/2020
    Primary completion :
    07/31/2024
    Completion :
    07/31/2024
    BCL2
    |
    JNJ-6665
    Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633)
    Phase 2
    Fred Hutchinson Cancer Center
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    01/25/2021
    Primary completion :
    12/31/2024
    Completion :
    12/31/2026
    HLA-DRB1
    |
    cyclophosphamide • fludarabine IV • busulfan • cyclosporin A microemulsion • Grafapex (treosulfan) • Neupogen (filgrastim) • cyclophosphamide intravenous
    A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia (NCT05849662)
    Phase 1/2
    Therapeutic Advances in Childhood Leukemia Cons...
    Recruiting
    Last update posted :
    05/20/2024
    Initiation :
    05/10/2024
    Primary completion :
    12/01/2028
    Completion :
    12/01/2029
    KRAS • NRAS • NF1 • PTPN11
    |
    KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation
    |
    Mekinist (trametinib) • cytarabine • azacitidine • fludarabine IV
    Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome (NCT03047993)
    Phase 1/2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    05/14/2024
    Initiation :
    11/15/2017
    Primary completion :
    03/16/2023
    Completion :
    03/16/2023
    TP53 • IDH1 • IDH2 • RUNX1 • ASXL1
    |
    RUNX1 mutation • ASXL1 mutation • EZH2 mutation
    |
    azacitidine • telaglenastat (CB-839)
    Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT04734990)
    Phase 1/2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/09/2024
    Initiation :
    07/07/2021
    Primary completion :
    09/11/2025
    Completion :
    09/11/2025
    TP53 • NRAS • RUNX1 • ASXL1 • SETBP1
    |
    TP53 mutation • NRAS mutation • ASXL1 mutation
    |
    azacitidine • seclidemstat (SP2577)
    Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases (NCT05800210)
    Phase 2
    University of Florida
    Recruiting
    Last update posted :
    05/08/2024
    Initiation :
    05/03/2024
    Primary completion :
    05/01/2026
    Completion :
    05/01/2027
    FLT3
    |
    FLT3 mutation • CBL mutation • Chr t(9;11)
    Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML (NCT05807932)
    Phase 1/2
    Heinrich-Heine University, Duesseldorf
    Recruiting
    Last update posted :
    05/01/2024
    Initiation :
    06/26/2023
    Primary completion :
    01/31/2026
    Completion :
    01/30/2028
    KRAS • TP53 • NRAS • IDH1 • IDH2 • NF1 • RUNX1 • KMT2A • PTPN11 • NUP214 • DEK • RIT1
    |
    KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation • CBL mutation
    |
    Venclexta (venetoclax) • cytarabine • fludarabine IV • Grafapex (treosulfan) • Amsidine (amsacrine)
    High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD (NCT05895201)
    Phase 1/2
    Indiana University
    Withdrawn
    Last update posted :
    04/29/2024
    Initiation :
    11/01/2023
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    HLA-DRB1 • HLA-B • HLA-C
    |
    bortezomib • cyclophosphamide
    Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML (NCT04139434)
    Phase 1
    Newave Pharmaceutical Inc
    Active, not recruiting
    Last update posted :
    04/24/2024
    Initiation :
    07/06/2020
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    BCL2
    |
    azacitidine • LP-108
    Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. (NCT04771572)
    Phase 1
    Newave Pharmaceutical Inc
    Recruiting
    Last update posted :
    04/24/2024
    Initiation :
    08/23/2021
    Primary completion :
    10/01/2025
    Completion :
    10/01/2025
    BCL2
    |
    LP-118
    TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT03816319)
    Phase 1
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    04/19/2024
    Initiation :
    08/30/2024
    Primary completion :
    12/11/2024
    Completion :
    12/11/2024
    CD4
    |
    TAK-243
    Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015)
    Phase 1
    City of Hope Medical Center
    Completed
    Last update posted :
    04/02/2024
    Initiation :
    10/29/2012
    Primary completion :
    02/02/2024
    Completion :
    02/02/2024
    HLA-DRB1
    |
    PD-1 expression
    |
    Promune (agatolimod)
    Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia (NCT03418038)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    03/23/2018
    Primary completion :
    12/01/2025
    Completion :
    03/01/2026
    IDH1 • BCL2 • IDH2 • DNMT3A • SF3B1 • TET2 • SRSF2 • U2AF1 • CD4 • ZRSR2
    |
    IDH2 mutation • DNMT3A mutation • TET2 mutation • SF3B1 mutation • EZH2 mutation • SRSF2 mutation • U2AF1 mutation
    |
    cisplatin • carboplatin • gemcitabine • Rituxan (rituximab) • cytarabine • cyclophosphamide • ifosfamide • oxaliplatin • etoposide IV • decitabine • dexamethasone • Truxima (rituximab-abbs) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • Hemady (dexamethasone tablets) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous • dexamethasone injection
    Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant (NCI-2016-00343) (NCT02684162)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    03/25/2024
    Initiation :
    06/22/2016
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    HLA-DRB1
    |
    guadecitabine (SGI-110)
    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant (NCT03326921)
    Phase 1
    Fred Hutchinson Cancer Center
    Suspended
    Last update posted :
    03/21/2024
    Initiation :
    02/23/2018
    Primary completion :
    10/16/2027
    Completion :
    07/16/2028
    HLA-A • CD4
    |
    HLA-A*02:01
    |
    fludarabine IV • HA-1 T TCR T Cell Immunotherapy
    AZD6738 for Patients With Progressive MDS or CMML (NCT03770429)
    Phase 1
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    08/05/2019
    Primary completion :
    05/31/2024
    Completion :
    05/31/2025
    SF3B1 • SRSF2 • U2AF1 • ZRSR2
    |
    SF3B1 mutation
    |
    ceralasertib (AZD6738)
    Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia (NCT01885689)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    02/10/2014
    Primary completion :
    12/27/2019
    Completion :
    12/30/2024
    HLA-B • HLA-C
    |
    sirolimus • clofarabine • melphalan
    Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm (NCI-2019-04959) (NCT04140487)
    Phase 1/2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    03/15/2024
    Initiation :
    12/17/2019
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    FLT3
    |
    FLT3-ITD mutation • FLT3 mutation • FLT3 D835
    |
    Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine